×
About 5,720 results

ALLMedicine™ Vitiligo Center

Research & Reviews  1,842 results

Electrocautery
https://emedicine.medscape.com/article/2111163-print

Jul 1st, 2022 - Background Electrocautery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to ac...

Electrocautery
https://emedicine.medscape.com/article/2111163-overview

Jul 1st, 2022 - Background Electrocautery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to ac...

Electrocautery
http://emedicine.medscape.com/article/2111163-overview

Jul 1st, 2022 - Background Electrocautery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to ac...

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

Jul 1st, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04811131

Jul 1st, 2022 - This study is a Phase 2a, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 0.3% cream in combination with NB-UVB phototherapy treatment in subjects with non-segmental facial vitiligo.

see more →

Guidelines  1 results

Guidelines for the management of vitiligo: the European Dermatology Forum consensus.
https://doi.org/10.1111/j.1365-2133.2012.11197.x
The British Journal of Dermatology; Taieb A, Alomar A et. al.

Aug 7th, 2012 - The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. T...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  191 results

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
https://clinicaltrials.gov/ct2/show/NCT03076554

Jul 1st, 2022 - Background Platinum-based chemotherapy is the standard of care for advanced unresectable thymic epithelial tumors (TETs). However more than half of these patients experience disease recurrence and require second-line therapy. There are no approved...

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04811131

Jul 1st, 2022 - This study is a Phase 2a, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-252 0.3% cream in combination with NB-UVB phototherapy treatment in subjects with non-segmental facial vitiligo.

Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy
https://clinicaltrials.gov/ct2/show/NCT03270241

Jun 30th, 2022 - This is a dermatology study of the effects of short-term NB-UVB treatment, standard phototherapy for Vitiligo patients. In the study, demographics information, three ascending dose of phototherapy, and small skin biopsies will be required of the p...

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04530344

Jun 27th, 2022 - The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed eit...

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
https://clinicaltrials.gov/ct2/show/NCT04487860

Jun 27th, 2022 - This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study. I

see more →

News  242 results

Assessing Treatment Delays for Vitiligo Patients: A Retrospective Chart Review
https://www.mdedge.com/dermatology/article/255409/pigmentation-disorders/assessing-treatment-delays-vitiligo-patients
Kavina Patel, MD, Fabiana C.P.s. Lopes, MD et. al.

Jun 14th, 2022 - Similar to other dermatologic conditions, barriers to early care in patients with vitiligo can exacerbate health disparities. 1 Delayed treatment of vitiligo is known to hamper successful disease stabilization and repigmentation, as therapies tend.

Pending further study, caution recommended in treating vitiligo patients with lasers, IPL
https://www.mdedge.com/dermatology/article/255226/pigmentation-disorders/pending-further-study-caution-recommended-treating
Doug Brunk

Jun 6th, 2022 - SAN DIEGO – The risk of laser or intense-pulsed light–induced vitiligo from treating vitiligo with either modality appears to be low, but caution is recommended until further studies are carried out. Those are the preliminary conclusions from a sy.

What’s ahead for laser-assisted drug delivery?
https://www.mdedge.com/dermatology/article/255160/dermatologic-surgery/whats-ahead-laser-assisted-drug-delivery
Doug Brunk

Jun 2nd, 2022 - SAN DIEGO – Twelve years ago, Merete Haedersdal, MD, PhD, and colleagues published data from a swine study, which showed for the first time that the ablative fractional laser can be used to boost the uptake of drugs into the skin. That discovery p.

JAK Inhibitor Therapies Continue to Show Promise in Patients With Vitiligo
https://www.medscape.com/viewarticle/971834

Apr 8th, 2022 - BOSTON — Patients with vitiligo treated with a topical formulation of the Janus kinase (JAK) inhibitor ruxolitinib had significant repigmentation after 1 year on the therapy, reported investigators from two randomized controlled trials presented a...

Wet Your Whistles: Alcohol-Induced Flushing With Use of Topical Calcineurin Inhibitors
https://www.mdedge.com/dermatology/article/252375/atopic-dermatitis/wet-your-whistles-alcohol-induced-flushing-use-topical
Emily C. Milam, MD, David E. Cohen, MD, MPH

Mar 3rd, 2022 - Practice Gap The topical calcineurin inhibitors (TCIs) tacrolimus and pimecrolimus are US Food and Drug Administration approved for the treatment of atopic dermatitis. 1 In addition, these 2 drugs are utilized off label for many other dermatologic.

see more →

Patient Education  6 results see all →